Background: HCV/HIV coinfection in people who inject drugs is a public health issue, which presents a variety of challenges to healthcare providers. The determinants of HCV/HIV coinfection in this population are nonetheless not well known. The aim of the present study is to identify the factors associated with HCV/HIV coinfection in people who inject drugs and enter drug-related treatment.

Methods: Linked serological and behavioral data were collected from people who entered 38 opioid substitution treatment clinics in central and southern Greece between January and December 2013. Three mutually exclusive groups were defined based on the presence of HCV and HIV antibodies. Group 1 clients had neither infection, Group 2 had HCV but not HIV, and Group 3 had HCV/HIV coinfection. Multinomial logistic regression analyses identified differences between groups according to socio-demographic, drug use and higher-risk behavioral characteristics.

Results: Our study population consisted of 580 people who injected drugs in the past 12 months (79.8 % males, with median age 36 years).79.4 % were HCV and 15.7 % HIV infected. Of those with complete serological data in both HCV and HIV indicators, 20.4 % were uninfected, 64.0 % HCV monoinfected, and 14.9 % HCV/HIV coinfected. HCV infection with or without HIV coinfection was positively associated with living alone or with a spouse/partner without children, prior incarceration, drug injecting histories of ≥10 years, and syringe sharing in the past 12 months, and negatively associated with never having previously been tested for HCV. HCV/HIV coinfection, but not HCV infection alone, was positively associated with residence in urban areas (relative risk ratio [RRR] = 4.8, 95 % confidence interval [CI]: 1.7-13.7,  = 0.004) and averaging >3 injections a day in the past 30 days (RRR = 4.5, 95 % CI: 1.6-12.8,  = 0.005), and negatively associated with using a condom in the last sexual intercourse.

Conclusions: People who inject drugs and live in urban areas and inject frequently have higher risk of coinfection. Findings highlight the need for scaling-up needle and syringe programs in inner city areas and promoting access of this population to screening and treatment, especially in prisons. The protective role of living with parents and children could inform the implementation of indicated interventions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918725PMC
http://dx.doi.org/10.1186/s41124-016-0017-5DOI Listing

Publication Analysis

Top Keywords

hcv/hiv coinfection
24
people inject
16
inject drugs
16
coinfection people
12
hcv hiv
12
drugs enter
8
opioid substitution
8
substitution treatment
8
hcv
8
hcv infection
8

Similar Publications

Hepatitis and human immunodeficiency virus (HIV) are major public health issues in developing countries, including Ethiopia. These viruses can be transmitted from mother to child during birth or through contact with contaminated blood. In many areas of Ethiopia, viral hepatitis and HIV infections are significant health concerns for pregnant women.

View Article and Find Full Text PDF

Background: The proportion of people living with HIV (PLWHIV) co-infected with HCV in Mexico was unknown. Our aim was to estimate the seroprevalence of HCV among adults with HIV in Mexico.

Methods: Using a complex-survey design, we collected blood samples and applied structured questionnaires between May 2nd, 2019 and February 17th, 2020 in a nationally, representative sample of adults receiving care for HIV-infection in 24 randomly selected HIV-care centres in 8 socio-demographically regions in Mexico.

View Article and Find Full Text PDF

Human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) are known as the most common blood-borne viral infections worldwide. Individuals referring to drop-in centers (DICs) are considered high-risk people exposed to infection with blood-borne viruses. The purpose of this study was to investigate the prevalence of HIV, HBV, and HCV infections among women referred to DICs in Lorestan Province, western Iran.

View Article and Find Full Text PDF

Background: Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C (CHC) in China, especially those with HCV GT3b, cirrhosis, hepato-cellular carcinoma (HCC), or HCV/hepatitis B (HBV), HCV/HIV, or HCV/HBV/HIV coinfection.

Methods: In this real-world prospective observational study, we recruited patients from the West China Hospital and Public Health Clinical Center of Chengdu in China.

View Article and Find Full Text PDF
Article Synopsis
  • Hepatitis C (HCV) in people who are also infected with HIV leads to faster liver disease progression compared to those with only HCV, potentially due to HLA-G, which suppresses immune responses.
  • A study analyzed liver samples from 59 patients with both chronic HCV and HIV to look at HLA-G levels in relation to liver disease severity.
  • The results showed that higher HLA-G expression was linked to more severe liver conditions but did not affect the effectiveness of HCV treatment, indicating HLA-G's complex role in disease progression in coinfected patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!